<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2856">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662684</url>
  </required_header>
  <id_info>
    <org_study_id>21589 Michelle Trial</org_study_id>
    <nct_id>NCT04662684</nct_id>
  </id_info>
  <brief_title>Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial</brief_title>
  <acronym>MICHELLE</acronym>
  <official_title>Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Science Valley Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Science Valley Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Michelle trial is expected to provide high-quality evidence around the role of extended&#xD;
      thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The devastating COVID-19 pandemic is associated with a high prothrombotic state.&#xD;
      It is unclear if the coagulation abnormalities occur because of the direct effect of SARS-CoV&#xD;
      2 or indirectly by the cytokine storm and endothelial damage, or by a combination of&#xD;
      mechanisms. There is a clear indication of in-hospital pharmacological thromboprophylaxis for&#xD;
      every patient with COVID-19 after bleed risk assessment. However, there is much debate&#xD;
      regarding the best dosage regimen, and there is no consensus on the role of extended VTE&#xD;
      prophylaxis.&#xD;
&#xD;
      Design: This study aims to evaluate the safety and efficacy of rivaroxaban 10 mg OD for&#xD;
      35+/-4 days versus no intervention after hospital discharge in COVID-19 patients who were at&#xD;
      increased risk for VTE and have received standard parenteral VTE prophylaxis during&#xD;
      hospitalization, with a composite efficacy endpoint of symptomatic VTE, VTE-related death,&#xD;
      and/or VTE detected by mandatory bilateral lower limbs venous duplex scan and computed&#xD;
      tomography pulmonary angiogram on day 35+/-4 post-hospital discharge.&#xD;
&#xD;
      Summary: The Michelle trial is expected to provide high-quality evidence around the role of&#xD;
      extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical&#xD;
      practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study aims to evaluate the safety and efficacy of rivaroxaban 10 mg OD for 35+/-4 days versus no intervention after hospital discharge in COVID-19 patients who were at increased risk for VTE and have received standard parenteral VTE prophylaxis during hospitalization, with a composite efficacy endpoint of symptomatic VTE, VTE-related death, and/or VTE detected by mandatory bilateral lower limbs venous duplex scan and computed tomography pulmonary angiogram on day 35+/-4 post-hospital discharge.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism and VTE related-death</measure>
    <time_frame>at day 35 +/- post hospital discharge</time_frame>
    <description>a composite efficacy endpoint of symptomatic VTE, VTE-related death, and/or VTE detected by mandatory bilateral lower limbs venous duplex scan and computed tomography pulmonary angiogram on day 35+/-4 post-hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>at day 35 +/- post hospital discharge</time_frame>
    <description>Incidence of major bleeding according to ISTH criteria.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>A composite of myocardial infarction, stroke, arrhythmias, heart failure, venous thromboembolism (VTE), and all-cause death.</measure>
    <time_frame>at day 35 +/- post hospital discharge</time_frame>
    <description>A composite of myocardial infarction, stroke, arrhythmias, heart failure, venous thromboembolism (VTE), and all-cause death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Days alive out of the hospital (DAOH) at 35 +/-4 days</measure>
    <time_frame>at day 35 +/- post hospital discharge</time_frame>
    <description>Days alive out of the hospital (DAOH) at 35 +/-4 days</description>
  </other_outcome>
  <other_outcome>
    <measure>D-dimer (Biomarker)</measure>
    <time_frame>at day 35 +/- 4 post hospital discharge</time_frame>
    <description>plasma level of D-dimers in ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>C reactive protein (Biomarker)</measure>
    <time_frame>at day 35 +/- 4 post hospital discharge</time_frame>
    <description>plasma level of C Reactive Protein in Î¼g/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>PAI-1 (Biomarker)</measure>
    <time_frame>at day 35 +/- 4 post hospital discharge</time_frame>
    <description>plasma level of PAI-1 in units/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>TFPI (Biomarker)</measure>
    <time_frame>at day 35 +/- 4 post hospital discharge</time_frame>
    <description>plasma level of TFPI in units/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>Thrombomodulin (Biomarker)</measure>
    <time_frame>at day 35 +/- 4 post hospital discharge</time_frame>
    <description>plasma level of Thrombomodulin in nM/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>IL-6 (Biomarker)</measure>
    <time_frame>at day 35 +/- 4 post hospital discharge</time_frame>
    <description>plasma level of IL-6 in pg/mL</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Covid19</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10mg OD for 35+/- 4 days post-hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>No intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and nonpregnant female patients 18 years of age or older&#xD;
&#xD;
          -  Positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for SARS-CoV-2&#xD;
             in a respiratory tract sample&#xD;
&#xD;
          -  Pneumonia confirmed by chest imaging&#xD;
&#xD;
          -  Additional risk factors for VTE, as indicated by a total modified International&#xD;
             Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk score of 4 or&#xD;
             higher&#xD;
&#xD;
          -  Have received thromboprophylaxis with low-molecular-weight heparin, fondaparinux, or&#xD;
             unfractionated heparin during the index hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Refusal of informed consent&#xD;
&#xD;
          -  Physician decision that involvement in the trial was not in the patient's best&#xD;
             interest&#xD;
&#xD;
          -  Patients with a medical indication for anticoagulation therapy at the time of&#xD;
             inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation,&#xD;
             mechanical valve prosthesis)&#xD;
&#xD;
          -  Platelets &lt; 50,000 / mm3&#xD;
&#xD;
          -  Patients with contraindications to anticoagulation (active bleeding, liver failure,&#xD;
             blood dyscrasia, or prohibitive hemorrhagic risk in the investigator's assessment)&#xD;
&#xD;
          -  Active cancer (excluding non-melanoma skin cancer) defined as cancer, not in remission&#xD;
             or requiring active chemotherapy or adjunctive therapies such as immunotherapy or&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or glycoprotein P (P-gp) (eg&#xD;
             protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong&#xD;
             inducers of CYP3A4 (how but not limiting rifampicin/rifampicin, rifabutin,&#xD;
             rifapentine, phenytoin, phenobarbital, carbamazepine or St. John's wort)&#xD;
&#xD;
          -  Creatinine clearance &lt;30 ml / min&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  known HIV infection&#xD;
&#xD;
          -  Presence of one of the following uncontrolled or unstable cardiovascular diseases:&#xD;
             stroke, ECG confirmed acute ischemia or myocardial infarction, and/or clinically&#xD;
             significant dysrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Ramacciotti, MD, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Science Valley Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Ramacciotti, MD, PhD</last_name>
    <phone>+551144688183</phone>
    <email>ramacciotti@svriglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leandro Agati, PhD</last_name>
    <phone>+551144688183</phone>
    <email>agati@svriglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Science Valley Research Institute</name>
      <address>
        <city>Santo AndrÃ©</city>
        <state>SÃ£o Paulo</state>
        <zip>09030370</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Agati, PhD</last_name>
      <phone>+551144688183</phone>
      <email>agati@svriglobal.com</email>
    </contact>
    <contact_backup>
      <last_name>Eduardo Ramacciotti, MD, PhD</last_name>
      <phone>+551144688183</phone>
      <email>ramacciotti@svriglobal.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Science Valley Research Institute</investigator_affiliation>
    <investigator_full_name>Eduardo Ramacciotti</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Rivaroxaban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Red Cap open file</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

